Collaborations between physicians or medical researchers and biopharmaceutical companies can benefit society by promoting the discovery and development of new medications that improve individual and public health. However, there are concerns that these relationships may create conflicts of interest due to the risk of undue influence on professional judgments thereby potentially jeopardizing the integrity of scientific investigations and the quality of patient care.
Lilly makes payments to health care providers only for legitimate, reasonable, and necessary services and in amounts that are no more than the fair market value for the services performed.
- Lilly appropriately compensates healthcare providers conducting Lilly sponsored or supported medical research for performing study procedures and collecting relevant data.
- When selecting service providers, Lilly chooses providers who are qualified and well suited to perform the services. Lilly does not preferentially select service providers who are customers for Lilly products and does not condition any service provider's selection upon the purchase of Lilly products.
- Lilly does not make payments to healthcare providers for the purpose of rewarding past or altering current/future prescribing practices.
- Lilly does not pay healthcare providers to gain experience with its products or to learn about its products.
Lilly believes policies that restrict the ability of innovators from engaging directly with medical professionals are an impediment to advancing medical knowledge and patient care.